Protecting retinal cells could save sight

Article

A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.

A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.

The breakdown of retinal cells known as photoreceptors is common to several diseases that cause blindness. In the diseases the researchers studied the photoreceptors were dying from a variety of causes, but common to all cases was the activation of a family of molecules called CREB1/ATF1. The team then attempted to determine if the molecules were contributing to the cell death or were being activated in an attempt to prolong cell life.

Studying retinas treated with a drug known to preserve photoreceptors, the researchers found much higher levels of CREB1/ATF1, suggesting the molecules act as part of the protective mechanism.

"Not only did we find that the drug activated the novel CREB1/ATF1 photoreceptor pathway, but we found that this activation was caused by stress," said Caroline Zeiss, associate professor of comparative medicine and ophthalmology at Yale School of Medicine, USA, in a statement. "This suggests that CREB/ATF1 may be an innate protective response that could be used to achieve broad spectrum preservation of the retina."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.